Folinic acid therapy fails to improve early Parkinson's disease: a two week placebo controlled clinical trial

J Neural Transm Park Dis Dement Sect. 1992;4(1):35-41. doi: 10.1007/BF02257620.

Abstract

Folinic acid (15 mg bid, po) was administered in a two week, double-blind, placebocontrolled, cross over clinical trial in 5 patients with Parkinson's disease (Hoehn and Yahr stage I or II). 4 patients had not been on L-dopa treatment prior to entering this trial and one patient was on a small dose of L-dopa. No significant improvement could be detected in this pilot study by clinical evaluation and motor performance assessed by a computer assisted motor performance test.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Double-Blind Method
  • Female
  • Humans
  • Leucovorin / adverse effects
  • Leucovorin / therapeutic use*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / psychology
  • Psychomotor Performance / drug effects

Substances

  • Leucovorin